These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 30893683)
1. Withdrawal Confounding in Randomized Controlled Trials of Antipsychotic, Antidepressant, and Stimulant Drugs, 2000-2017. Récalt AM; Cohen D Psychother Psychosom; 2019; 88(2):105-113. PubMed ID: 30893683 [TBL] [Abstract][Full Text] [Related]
2. Discontinuing Psychotropic Drugs from Participants in Randomized Controlled Trials: A Systematic Review. Cohen D; Recalt A Psychother Psychosom; 2019; 88(2):96-104. PubMed ID: 30923288 [TBL] [Abstract][Full Text] [Related]
3. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555 [TBL] [Abstract][Full Text] [Related]
4. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials. Kishi T; Matsuda Y; Iwata N; Correll CU J Clin Psychiatry; 2013 Dec; 74(12):e1169-80. PubMed ID: 24434105 [TBL] [Abstract][Full Text] [Related]
5. Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified? Emsley R; Fleischhacker WW Schizophr Res; 2013 Nov; 150(2-3):427-33. PubMed ID: 24094881 [TBL] [Abstract][Full Text] [Related]
6. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Dilsaver SC Drug Saf; 1994 Feb; 10(2):103-14. PubMed ID: 7912078 [TBL] [Abstract][Full Text] [Related]
7. An Open-Label Discontinuation Trial of Long-Term, Off-Label Antipsychotic Medication in People With Intellectual Disability: Determinants of Success and Failure. de Kuijper GM; Hoekstra PJ J Clin Pharmacol; 2018 Nov; 58(11):1418-1426. PubMed ID: 29920689 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. Helfer B; Samara MT; Huhn M; Klupp E; Leucht C; Zhu Y; Engel RR; Leucht S Am J Psychiatry; 2016 Sep; 173(9):876-86. PubMed ID: 27282362 [TBL] [Abstract][Full Text] [Related]
9. Withdrawal effects confounding in clinical trials: another sign of a needed paradigm shift in psychopharmacology research. Cohen D; Recalt A Ther Adv Psychopharmacol; 2020; 10():2045125320964097. PubMed ID: 33224467 [TBL] [Abstract][Full Text] [Related]
10. Interventions to help patients withdraw from depression drugs: A systematic review. Gøtzsche PC; Demasi M Int J Risk Saf Med; 2024; 35(2):103-116. PubMed ID: 37718853 [TBL] [Abstract][Full Text] [Related]
11. Concomitant Use of Atypical Antipsychotics With Other Psychotropic Medication Classes and the Risk of Type 2 Diabetes Mellitus. Burcu M; Zito JM; Safer DJ; Magder LS; dosReis S; Shaya FT; Rosenthal GL J Am Acad Child Adolesc Psychiatry; 2017 Aug; 56(8):642-651. PubMed ID: 28735693 [TBL] [Abstract][Full Text] [Related]
12. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD). Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z; J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285 [TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study. Amsterdam JD; Lorenzo-Luaces L; Soeller I; Li SQ; Mao JJ; DeRubeis RJ J Affect Disord; 2015 Oct; 185():31-7. PubMed ID: 26143402 [TBL] [Abstract][Full Text] [Related]
14. Continuation and maintenance treatments for depression in older people. Wilkinson P; Izmeth Z Cochrane Database Syst Rev; 2012 Nov; 11():CD006727. PubMed ID: 23152240 [TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Emsley R; Chiliza B; Asmal L; du Plessis S; Phahladira L; van Niekerk E; van Rensburg SJ; Harvey BH Schizophr Res; 2014 Sep; 158(1-3):230-5. PubMed ID: 24996507 [TBL] [Abstract][Full Text] [Related]